MNMD Valuation

Mind Medicine (MindMed) Inc

Add to Watchlist

Advanced Chart

9.410

-0.13(-1.363%)1D

Overview
Forecast
Valuation
Earnings

MNMD Relative Valuation

MNMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MNMD is overvalued; if below, it's undervalued.

Historical Valuation

Mind Medicine (MindMed) Inc (MNMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.90. The fair price of Mind Medicine (MindMed) Inc (MNMD) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：9.54

Fair

-4.79

Trailing

Forward

-3.44

EV/EBITDA

Mind Medicine (MindMed) Inc. (MNMD) has a current EV/EBITDA of -3.44. The 5-year average EV/EBITDA is -14.05. The thresholds are as follows: Strongly Undervalued below -65.45, Undervalued between -65.45 and -39.75, Fairly Valued between 11.64 and -39.75, Overvalued between 11.64 and 37.34, and Strongly Overvalued above 37.34. The current Forward EV/EBITDA of -3.44 falls within the Historic Trend Line -Fairly Valued range.

-3.28

EV/EBIT

Mind Medicine (MindMed) Inc. (MNMD) has a current EV/EBIT of -3.28. The 5-year average EV/EBIT is -9.33. The thresholds are as follows: Strongly Undervalued below -43.44, Undervalued between -43.44 and -26.38, Fairly Valued between 7.73 and -26.38, Overvalued between 7.73 and 24.78, and Strongly Overvalued above 24.78. The current Forward EV/EBIT of -3.28 falls within the Historic Trend Line -Fairly Valued range.

0.00

Mind Medicine (MindMed) Inc. (MNMD) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-4.81

P/OCF

Mind Medicine (MindMed) Inc. (MNMD) has a current P/OCF of -4.81. The 5-year average P/OCF is -21.72. The thresholds are as follows: Strongly Undervalued below -87.39, Undervalued between -87.39 and -54.55, Fairly Valued between 11.12 and -54.55, Overvalued between 11.12 and 43.95, and Strongly Overvalued above 43.95. The current Forward P/OCF of -4.81 falls within the Historic Trend Line -Fairly Valued range.

-4.73

P/FCF

Mind Medicine (MindMed) Inc. (MNMD) has a current P/FCF of -4.73. The 5-year average P/FCF is -20.70. The thresholds are as follows: Strongly Undervalued below -82.59, Undervalued between -82.59 and -51.64, Fairly Valued between 10.24 and -51.64, Overvalued between 10.24 and 41.18, and Strongly Overvalued above 41.18. The current Forward P/FCF of -4.73 falls within the Historic Trend Line -Fairly Valued range.

Mind Medicine (MindMed) Inc (MNMD) has a current Price-to-Book (P/B) ratio of 3.90. Compared to its 3-year average P/B ratio of 2.00 , the current P/B ratio is approximately 94.71% higher. Relative to its 5-year average P/B ratio of 11.27, the current P/B ratio is about -65.40% higher. Mind Medicine (MindMed) Inc (MNMD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -26.78%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -18.42% , the current FCF yield is about -100.00% lower.

3.90

P/B

Median3y

2.00

Median5y

11.27

-14.77

FCF Yield

Median3y

-26.78

Median5y

-18.42

Competitors Valuation Multiple

The average P/S ratio for MNMD's competitors is 0.00, providing a benchmark for relative valuation. Mind Medicine (MindMed) Inc Corp (MNMD) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MNMD.O

Mind Medicine (MindMed) Inc

Aquestive Therapeutics Inc

Day One Biopharmaceuticals Inc

Theravance Biopharma Inc

Performance Decomposition

Market capitalization of MNMD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MNMD in the past 1 year is driven by Unknown.